In-Vitro IBD Diagnostic Market Analysis

Report ID: 3414
Published Date: Dec 26, 2024
Report Format: PDF, PPT

Buy Now

In-Vitro Inflammatory Bowel Disease (IBD) Diagnostic Segmentation

The in-vitro inflammatory bowel disease (IBD) diagnostic market is segmented by product into assays/biomarkers and analyzers. Out of these, the assays/biomarkers segment is anticipated to hold the highest market share throughout the forecast period. The segment is also anticipated to grow with the highest CAGR of 5.6% during the forecast period. Further, on the basis of disease type, the market is segmented into ulcerative colitis and Crohn’s disease, out of which, the ulcerative colitis segment is anticipated to hold the highest market share and also grow with the highest CAGR of 5.7% during the forecast period. Based on disease stage, the market is segmented into mild, moderate, and severe, out of which, the severe segment is anticipated to hold the largest market revenue of USD 1225.89 Million by the end of 2028, up from a revenue of USD 823.27 Million in 2019. Further, on the basis of test type, the in-vitro inflammatory bowel disease (IBD) diagnostic market is segmented into blood tests, stool tests, antibody tests, and biopsy. Out of these segments, the blood tests segment is anticipated to hold the highest market share and also attain a market revenue of USD 931.51 Million by the end of 2028. On the basis of patient demography, the market is segmented into pediatric, adults, and geriatric, out of which, the adults segment is anticipated to hold the largest revenue of USD 1592.15 Million by the end of 2028. The market is also segmented on the basis of end-user into hospitals, clinics, diagnostic laboratories, and others. Out of these segments, the hospitals segment is projected to hold the highest market share and also attain a revenue of USD 1297.52 Million by the end of 2028. Moreover, on the basis of test method, the market is segmented into PETIA, ELISA, rapid, and others, out of which, the ELISA segment is expected to garner the highest in-vitro inflammatory bowel disease (IBD) diagnostic market revenue of USD 663.62 Million by the end of 2028, up from a revenue of USD 428.08 Million in 2019.

Our in-depth analysis of the global market includes the following segments:

Product	Assays/Biomarkers Analyzers
Disease Type	Ulcerative Colitis Crohn Disease
Disease Stage	Mild, Moderate, Severe
Test Type	Blood Tests, Stool Tests, Antibody Tests, Biopsy
Patient Demography	Pediatric Adults, Geriatric
End-user	Hospitals Clinics Diagnostic Laboratories

Browse key industry insights with market data tables & charts from the report:

In-Vitro Inflammatory Bowel Disease Diagnostic Market Size Report 2037 [2025 Updated]

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of in-vitro IBD diagnostic is assessed at USD 2.02 billion.

In-Vitro Inflammatory Bowel Disease (IBD) Diagnostic Market size was over USD 1.93 billion in 2024 and is projected to reach USD 3.78 billion by 2037, growing at around 5.3% CAGR during the forecast period i.e., between 2025-2037.

North America industry is estimated to account for largest revenue share of 44% by 2037, North America industry is estimated to account for largest revenue share of 44% by 2037

The major players in the market are are DiaSorin S.p.A., American Laboratory Products Company, Ltd. (d/b/a ALPCO Diagnostics), Quidel Corporation, CerTest Biotec, S.L., BUHLMANN Laboratories AG, and others.